Thomas K. Equels, CEO at AIM ImmunoTech Inc. (AIM), bought 14,535 shares at $1.72 ($25K) on 2020-12-17, disclosed to the SEC on 2020-12-17.
High-signal trade — passes our conviction filters but the AI narrative is still being generated. Check back shortly.
Nothing distinguishes this filing.
| Filing → |
| AIM | BUY | 2020-09-03 | $25K | — | Filing → |
| AIM | BUY | 2020-08-21 | $25K | — | Filing → |
| HEB | BUY | 2019-06-27 | $12K | — | Filing → |